quantisnow
FeedTopReportsPricing
⌘K
Live feed
20:15:44·27d
INSIDERFiling
AnaptysBio Inc. logo

SEC Form 4 filed by Faga Daniel

ANAB· AnaptysBio Inc.
Health Care
Original source

Companies

  • ANAB
    AnaptysBio Inc.
    Health Care

Recent analyst ratings

  • Jan 7UpdateUBS$70.00
  • Oct 13UpdateBarclays$78.00
  • Jun 4UpdateH.C. Wainwright$38.00
  • Feb 4UpdateWolfe Research$25.00
  • Dec 11UpdateH.C. Wainwright$19.00
  • Dec 2UpdateBTIG Research-

Related

  • PR3d
    Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
  • INSIDER20d
    SEC Form 3 filed by new insider Gray Susannah
  • INSIDER22d
    SEC Form 4 filed by Schmid John P.
  • INSIDER22d
    SEC Form 3 filed by new insider Anaptysbio, Inc
  • SEC27d
    AnaptysBio Inc. filed SEC Form 8-K: Regulation FD Disclosure
  • PR27d
    First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement
  • PR27d
    Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics
  • PR27d
    Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022